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A summary (= abstract) of not more than 250 words: 
 
Congenital disorders of glycosylation (CDG) represent an expanding group of 
inherited diseases. One of them, ALG8 deficiency (CDG-Ih), leads to protein N-glycosylation 
defects caused by malfunction of glucosyltransferase 2 (Dol-P-Glc:Glc1-Man9-GlcNAc2-P-P-
Dol glucosyltransferase) resulting in inefficient addition of the second glucose residue onto 
lipid-linked oligosaccharides. So far, only five patients have been described with ALG8 
deficiency. We present a new patient with neonatal onset. The girl was born at 29th week of 
gestation complicated by oligohydramnion. Although the early postnatal adaptation was 
uneventful (APGAR score 8 and 9 at the 5th and 10th minutes), generalized oedema, 
multifocal myoclonic seizures, and bleeding due to combined coagulopathy were present 
since the first day. Diarrhea progressing to the protein-losing enteropathy with ascites and 
pericardial effusion developed in the 3rd week of life. Pharmacoresistant seizures and cortical, 
cerebellar and optic nerves atrophy indicated neurological involvement. No symptoms of liver 
disease except coagulopathy were observed, however steatofibrosis with cholestasis was 
found at autopsy. The girl died at the age of 2 months due to the progressive general oedema, 
bleeding and cardio-respiratory insufficiency. Molecular analysis revealed two heterozygous 
mutations in the ALG8 gene: c.139A>C (p.T47P) and the novel mutation c.1090C>T 
(p.R364X). Conclusion: The prognosis of patients with ALG8 deficiency is unfavorable. 
Majority of affected children have early onset of the disease with heterogeneous symptoms 
including multi-organ dysfunction, coagulopathy and protein losing enteropathy.  
Neurological impairment is not a general clinical symptom, but it has to be taken into 
consideration when thinking about ALG8 deficiency.   
Supported by: LSHM-CT-2005-512131-EUROGLYCANET and MSM0021620806. 
 
A concise 1 sentence take-home message (synopsis) of the article, outlining what the reader learns from the 
article (this is usually printed on the (inside) back cover of JIMD). 
 
Clinical course of the disease in our patient further expands the awareness of symptoms 
diversity in patients with ALG8 deficiency, which includes multi-organ dysfunction with 
protein losing enteropathy, coagulopathy and central nervous system involvement. 
 
An abbreviated title for the running head. 
 
ALG8 deficiency  
 
References to electronic databases  
OMIM 608104 
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A list of abbreviations. 
 
CDG - congenital disorder of glycosylation 
Dol - dolichol 
APTT - activated partial thromboplastin time 
IEF – isoelectric focusing 
PMM – phosphomannomutase 
PMI – phosphomannose isomerase 
LLO – lipid-linked oligosaccharide  
NLO – protein N-linked oligosaccharide 
CDT - carbohydrate-deficient transferrin 
PLE – protein-losing enteropathy 
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SUPPLEMENTARY MATERIAL for ON-LINE publishing 
Introduction 
Congenital disorders of glycosylation (CDG syndromes) comprise a large group of 
genetic diseases resulting from defects in the synthesis and the processing of glycans (Jaeken 
and Matthijs 2007). ALG8 deficiency (CDG-Ih; OMIM 608104) is caused by pathological 
mutations in the ALG8 gene (Chantret et al. 2003) coding for the enzyme glucosyltransferase 
2 (Dol-P-Glc:Glc1-Man9-GlcNAc2-P-P-Dol glucosyltransferase). This enzyme is responsible 
for the addition of the second glucose residue onto the growing lipid-linked oligosaccharide 
(LLO) chain (Chantret et al. 2003). The ALG8 gene is located on chromosome 11 and spans 
38.7 kbp. Translation of its 1404 nucleotide-long open reading frame, organized in 13 exons 
results in a 467 amino acid long product.  
So far, only five patients with ALG8 deficiency have been described (Charlwood et al. 
1997; Chantret et al. 2003; Schollen et al. 2004; Eklund et al. 2005), presenting with 
dysmorphic features, hypotonia, oedema, coagulopathy, gastrointestinal disorders including 
protein-losing enteropathy (PLE), hepatomegaly and cardio-respiratory problems. Four 
patients had neonatal onset and deceased in early childhood. One patient (Chantret et al. 
2003) manifested later at the age of 4 month and survived beyond 3 years of age.  
The aim of our study was to present a detailed clinical picture of a new ALG8 
deficient patient with neonatal onset to further expand the general knowledge about the 
clinical symptoms in this disorder.  
 
 
Case report 
The girl was the first child of healthy, unrelated Caucasian parents. The pregnancy after in 
vitro fertilization was complicated with oligohydramnion progressing to anhydramnion. The 
child was born at 29th week of gestation with a birth weight of 1420 g and length of 38 cm by 
acute caesarean section. Generalized oedema (anasarca) and mild hypotonia were observed 
since birth. Although, the early postnatal adaptation was feasible with APGAR score 8 and 9 
at the 5th and 10th minutes, respectively, already during the first day of life multifocal 
myoclonic seizures and clinical signs of severe anemia developed. She was ventilated and 
inotropic treatment was initiated. Each sucking from endotracheal tube was complicated by 
mild bleeding episodes. Laboratory analyses at that time revealed pancytopenia (leucocytes 
2.6.109/l, controls 5.5; hemoglobin 85 g/l, controls 145; thrombocytopenia 61.109/l, 
controls 150) and severe combined coagulopathy with very low levels of factor XI (2% in 
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comparison to controls), antithrombin III (20%) and protein C (2%). Activated partial 
thromboplastin time was markedly prolonged (APTT >180s). Almost no improvement of the 
coagulation status was seen after frequent administration of fresh frozen plasma, antithrombin 
III, protein C and factor VIIa concentrate. Hemorrhagic diathesis with bleeding necessitated 
repeated administration of packed red blood cells. 
Although the clinical status seemed stabilized, since 3rd week of life progressive 
diarrhea, nasogastric tube feeding intolerance, abdominal distension followed on development 
of ascites and pericardial effusion were observed, as well as hypoalbuminemia (21.6 g/l, 
controls 35 g/l). However, the bleeding constantly dominated over tendency to thrombosis, 
thrombosis of vena cava inferior was documented at the age of one month. As a consequence 
of cardiac insufficiency and thrombotic episodes, liver congestion and portal hypertension 
developed leading to marked hepatosplenomegaly.  
Oedema was permanent with progressive course. Even though we did not study alfa-1-
antitrypsin clearance, the diagnosis of PLE was highly probable based on the fact that to 
maintain the normal concentration of albumin and immunoglobulins in blood necessitated 
practically continuous infusion of albumin (10% solution) and immunoglobulins substitution 
and on the fact that diarrhea persisted and losses of albumin into the urine was minimal.  
The seizures were under control on phenobarbital treatment, but than generalized tonic 
seizures appeared at the age of 6 weeks. Brain ultrasound and eye investigations did not show 
any pathological findings till the age of 6 weeks, when mild cerebral cortical and atrophy and 
bilateral optic nerve atrophy was observed.  
The girl was oxygen dependent on artificial lung ventilation or nasal CPAP until her 
death at the age of 2 months. The steatofibrosis with cholestasis found at the autopsy was 
striking, since no laboratory signs of liver failure or marked liver dysfunction were observed 
during the patients´ life. Brain post-mortem studies revealed mild cerebellar atrophy, but did 
not show any specific signs of cortical dysgenesis not even periventricular area changes 
typical for premature newborns.  
The immediate cause of death was the progressive general oedema, bleeding and 
cardio-respiratory insufficiency leading to the multi-organ failure.  
 
Ethics 
The study was carried out in accordance with the Declaration of Helsinki of the World 
Medical Association and was approved by the Committee of Medical Ethics of the Faculty of 
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Medicine and General Teaching Hospital in Prague. Informed consent was obtained from the 
parents. 
 
Methods: 
Biochemical methods: 
IEF of serum transferrin was carried out as described by van Eijk and van Noort  (van 
Eijk and van Noort 1992). Iron-saturated serum was incubated overnight at 37˚C with 
neuraminidase from Clostridium perfringens (Boehringer), and subsequently separated by 
SDS- PAGE (5%T, 3%C; pH 3-10). PMM and PMI activities were measured in isolated 
lymphocytes according to the procedure described by Van Schaftingen and Jaeken  (Van 
Schaftingen and Jaeken 1995). 
LLO and NLO were prepared from control and patient fibroblasts as described 
previously (Haeuptle et al. 2008). Briefly, the oligosaccharides were metabolically labelled by 
incorporation of 3[H]-mannose. The LLO were extracted with organic solvents and 
hydrolysed by mild acid treatment. NLO were released from glycoproteins by incubation with 
PNGase F (New England BioLabs). Prior to HPLC analysis, the oligosaccharides were 
purified by ionic and hydrophobic chromatography.  
 
Molecular methods: 
All 13 exons of ALG8 gene amplified from patients gDNA were analyzed on an ABI 
PRISM 3100-Avant Genetic Analyzer (Applied Biosystems). The c.139A>C mutation was 
confirmed by restriction fragment length polymorphism using the MnlI restriction 
endonuclease. For confirmation of the c.1090C>T mutation, we designed mismatch primers 
for the HpaII enzyme. 
 
Results: 
Biochemical analyses: 
The possible diagnosis of CDG in this patient was confirmed by detection of 
hypoglycosylated transferrin isoforms by IEF. The analysis revealed an abnormal 
glycosylation pattern, with decreased tetrasialo- and increased disialo- and asialo- transferrin, 
which is typical for CDG type I. Neuraminidase treatment excluded the possibility of a 
transferrin polymorphism. PMM2 and PMI activities measured in isolated lymphocytes and 
cultivated fibroblasts were normal, thus excluding CDG-Ia and CDG-Ib. 
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LLO analysis: 
In order to detect a possible defect in LLO assembly, skin fibroblasts isolated from the 
patient were labeled with 3[H]-mannose, and the glycans released from the lipid carrier were 
analyzed by HPLC. The LLO profile of the patient showed the accumulation of incomplete 
precursor structures corresponding to GlcNAc2Man9 and GlcNAc2Man9Glc1 (Figure 1, left 
panel). This pattern is typical for ALG8 deficiency (CDG-Ih) (Chantret et al. 2003). 
The accumulation of Dol-PP- GlcNAc2Man9- observed in the patient may be due to 
the deglucosylation of Dol-PP-GlcNAc2Man9Glc1 by ER glucosidase II, that has arisen due to 
inefficient addition of the second glucose residue by the ALG8 glucosyltransferase. 
 
NLO analysis: 
The NLO analysis revealed an HPLC profile comparable to that obtained from healthy 
control subjects (Figure 1, right panel). This is in accordance with thin layer chromatography 
analysis of NLO in an earlier ALG8 deficient patient (Chantret et al. 2003).  
 
Molecular analyses: 
Two ALG8 mutations in heterozygous form were detected in the patient. The first 
mutation (c.139A>C), already described in literature (Schollen et al. 2004), was combined 
with a novel mutation c.1090C>T. The index mutation, which is translated into the missense 
mutation p.T47P, was inherited from the father. The c.1090C>T mutation resulting in a 
premature stop codon (p.R364X) was found in heterozygous form in the mother, whereas it 
could not be found in 150 healthy controls. 
 
Discussion:  
The clinical course of the disease in our patient demonstrates, similar to the published 
cases (see Table 1), that the principal clinical and laboratory pathology is hemato-intestinal 
presentation. The majority of the patients were delivered prematurely and the first clinical 
symptoms, especially PLE, were presented during the first weeks of life. Only in one patient 
(surviving beyond three years of age) PLE and diarrhea developed later at the age of 4 
months.  
Anemia, pancytopenia, hypoalbuminemia and coagulopathy were observed in most 
patients. Coagulopathy in patients with ALG8 deficiency appears to be caused by a 
combination of hypoproduction of both, clotting factors and their inhibitors, and their 
increased consumption during chronic disseminated intravascular coagulation. The 
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coagulopathy in our patient seems to be more accentuated with profound bleeding in contrast 
to patients with other CDG syndromes. Difficult-to-treat hypoalbuminemia and coagulopathy 
resulted in the development of ascites, pericardial effusion, bleeding and early death. 
Although craniofacial dysmorphy, inverted nipples and atypical fat pads were not 
present in our patient, dysmorphy was observed in three reported cases of ALG8 deficiency 
(Schollen et al. 2004; Eklund et al. 2005), whereas inverted nipples and fat pads were noticed 
in one case (Charlwood et al. 1997). Since osteopenia, cataracts (Eklund et al. 2005), lung 
hypoplasia (Schollen et al. 2004) and retinopathy (Chantret et al. 2003) were only found in a 
single child, we deduce that these symptoms cannot be assigned as typical for ALG8 deficient 
patients. 
We did not observe elevated aminotransferases, but pronounced steatofibrosis with 
cholestasis was found at autopsy. Based on revision of clinical and laboratory reports from all 
six patients including our case, it seems that also mild tubulopathy and proteinuria belong to 
typical ALG8 deficiency symptoms. In addition, renal cortical and medullar microcysts were 
found in our patient.   
Until the fifth case was published in 2005 by Eklund and colleagues (Eklund et al. 
2005), ALG8 deficiency had been presented as a type of CDG without neurological 
manifestations (Schollen et al. 2004). Eklund et al. described a patient, who died at the age of 
16 months and presented with psychomotor delay, hypotonia and leukoencephalopathy. In our 
case, we also observed marked hypotonia and multifocal myoclonic seizures since birth, 
bilateral optic nerve atrophy, cerebral cortical atrophy and mild cerebellar atrophy. On the 
other hand, the patient studied by Chantret and coworkers (Chantret et al. 2003) survived 
beyond three years (Eklund et al. 2005) and had no signs of any neurological impairment and 
strikingly, PLE and diarrhea subsequently disappeared. The mild clinical features of this 
patient could be explained by an elevated residual ALG8 expression. In summary, 
neurological impairment is not a general clinical symptom, but it has to be taken into 
consideration when thinking about ALG8 deficiency.   
 
Conclusion: 
We present a new patient with ALG8 deficiency (CDG-Ih), the sixth case described to 
date. The course of the disease in this new ALG8 case further expands the awareness of 
clinical symptoms diversity, which include multiorgan dysfunction with PLE, liver, kidney 
and central nervous system involvements and combined coagulopathy. Furthermore, we also 
identified a novel pathological mutation c.1090C>T (p.R364X) in the ALG8 gene. The 
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diagnostics enabled genetic counseling and successful prenatal diagnostic in the affected 
family.  
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